← Leaderboards
Dmitriy Zamarin
Sloan-Kettering Inst Can Research
$3,530,063
Attributed
$3,530,063
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,530,063 · 2
By mechanism
R01$3,530,063 · 2
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Danny Khalil$1,315,170
- Hikmat Al-Ahmadie$4,559,862
- Sarat Chandarlapaty$10,852,142
- Jedd D. Wolchok$10,212,450
- Jose Baselga$1,310,766
Others in their field
Other Rising Stars on “T-Cell Receptor Repertoire”
- Steven Bradfute · Albert Einstein College Of Medicine$3,407,726
- Jesse Cedarbaum · Yale University$2,361,361
- Peter Skene · Seattle Children'S Hospital$2,338,140
- Etienne Caron · Yale University$2,184,871
- Mark Yarchoan · Johns Hopkins University$2,085,515
- Nduka Mgbechinyere Amankulor · University Of Pennsylvania$2,082,285
Research focus
T-Cell Receptor RepertoireCellsNeoplastic CellT-Cell ReceptorTumor MicroenvironmentT Cell Receptor Repertoire SequencingExhibitsImmunotherapyPeripheral BloodResponseT-LymphocyteTumorAntigen-Presenting CellsViralClinical TrialsBloodGeneticImmune Checkpoint BlockadeAnti-Tumor Immune ResponsePeripheralPhenotypeBiomarker IdentificationBiological MarkersBioinformatics
Grant awards (8)
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION$611,086
R01 · FY2025 · CA · contact PI
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation$529,039
R01 · FY2025 · CA · contact PI
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION$590,392
R01 · FY2024 · CA · contact PI
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation$536,602
R01 · FY2024 · CA · contact PI
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation$595,374
R01 · FY2023 · CA · contact PI
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION$565,064
R01 · FY2023 · CA · contact PI
POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION$79,305
R01 · FY2023 · CA · contact PI
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation$23,201
R01 · FY2023 · CA · contact PI